Visa (NYSE: V) closed fiscal 2026 with a quarter that matched the script. Net revenue of $12.1 billion, up 13%. Non-GAAP EPS of $3.48, a 17% gain that beat the Street by about four cents. The headline numbers were in line with expectations. The interest sits elsewhere.
Two moves buried in the release carry more weight than the print itself: a $2.4 billion cash acquisition of BioCatch, a fraud-intelligence firm, and a notable slowdown in the pace of share repurchases.
Start with the buyback. Visa repurchased $4.0 billion of class A stock in the quarter, down from $5.2 billion in Q3 and $5.5 billion in Q1. For the full year, repurchases totaled $20.5 billion, up from $18.3 billion in fiscal 2025. The quarterly trajectory is what matters. The company also deposited $405 million into its litigation escrow account in September, which has the same EPS effect as a repurchase. But the raw buyback number is cooling. At an average cost of $369.12 per share in Q4, Visa paid a higher price for fewer shares than it did earlier in the year. Not a red flag. A signal that management sees better uses for cash than retiring stock at these levels.
The BioCatch deal is that use. The $2.4 billion cash price is small relative to Visa's $14.2 billion cash pile. The strategic direction is clear. Fraud intelligence is becoming a competitive battleground in payments. Visa is paying up to own behavioral biometrics rather than licensing it. The deal is expected to close by fiscal Q2 2027. It will add to the company's "trust as a growth vector" narrative, as CEO Ryan McInerney put it. The acquisition also explains why the buyback pace is easing: management is redeploying capital into a higher-growth, higher-margin area of the payments stack.
Underneath the in-line quarter, the revenue mix tells a more nuanced story. Cross-border volume excluding intra-Europe grew 14% in Q4, matching the prior quarter's pace. Processed transactions rose 10% to 74.2 billion. Payments volume growth held at 9%. The standout was other revenue, which jumped 40% to $1.6 billion, driven by value-added services. That line is becoming a meaningful contributor. Its growth rate is more than double the core payments volume growth.
Client incentives, the rebates Visa pays to issuers and acquirers, rose 21% to $5.1 billion. A faster clip than net revenue. That is the cost of competition. Worth watching whether incentive growth continues to outpace revenue growth into fiscal 2027.
Margins were steady. Non-GAAP operating expenses rose 12% in the quarter, roughly in line with revenue growth, with marketing and personnel costs leading. The GAAP effective tax rate came in at 18.5%. The non-GAAP rate was 18.4%. Both essentially flat year over year. No margin compression story here. No margin expansion story either. The operating leverage that Visa historically delivered is being reinvested, partly into marketing and partly into the BioCatch integration.
Full-year numbers reinforce the trajectory. Net revenue hit $45.9 billion, up 15%, which management called the strongest growth in over 15 years excluding the post-pandemic recovery and acquisitions. Non-GAAP EPS rose 16% to $13.27. The dividend increase to $0.78 per share, a 16% bump, is a modest but consistent signal of confidence. Combined repurchases and dividends totaled $25.6 billion for the year, a hefty return. The composition is shifting toward dividends and away from buybacks.
What to watch next is the BioCatch close and the incentive line. If client incentives keep growing faster than revenue, the take rate will keep compressing. That is a structural drag on the model. If BioCatch closes on schedule and starts contributing to the other revenue line, the 40% growth rate in that segment could hold. The buyback slowdown is the quieter tell: Visa is choosing to invest in fraud tech over buying its own stock. That is a bet on the next decade of payments, not the next quarter.